Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine

The primary objective of the IMPACT-NAC trial is to assess the effects of N-acetylcysteine on survival and hospital length of stay in adults admitted to the emergency department with acute infection or sepsis and evidence of liver dysfunction. The main question it aims to answer is: does N-acetylcysteine increase the number of days alive and out of the hospital within the first 14 days after enrolment in the trial? To answer this question, we will conduct a randomized, double-blinded controlled trial of 360 participants. Participants will be randomized to either N-acetylcysteine or placebo (normal saline without active drugs). This will be administered as an infusion during four hours within the first day of hospital admission.

NCT Number	NCT07273071
Lead Sponsor	Theis S. Itenov Collaborators: University Hospital Bispebjerg and Frederiksberg
Conditions	Sepsis, Acute Infection, Severe Infection
Enrollment	360 participants
Start Date	2026-07
Primary Completion	2027-12 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-03-27